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Abstract
Introduction: Neuron specific enolase (NSE) has been proven effective in predicting neurological outcome after 
cardiac arrest with a current cut off recommendation of 33 μg/l. However, most of the corresponding studies were 
conducted before the introduction of mild therapeutic hypothermia (MTH). Therefore we conducted a study 
investigating the association between NSE and neurological outcome in patients treated with MTH
Methods: In this prospective observational cohort study the data of patients after cardiac arrest receiving MTH (n = 97) 
were consecutively collected and compared with a retrospective non-hypothermia (NH) group (n = 133). Serum NSE 
was measured 72 hours after admission to ICU. Neurological outcome was classified according to the Pittsburgh 
cerebral performance category (CPC 1 to 5) at ICU discharge.
Results: NSE serum levels were significantly lower under MTH compared to NH in univariate analysis. However, in a 
linear regression model NSE was affected significantly by time to return of spontaneous circulation (ROSC) and 
ventricular fibrillation rhythm but not by MTH. The model for neurological outcome identified NSE, NSE*MTH 
(interaction) as well as time to ROSC as significant predictors. Receiver Operating Characteristic (ROC) analysis revealed 
a higher cutoff value for unfavourable outcome (CPC 3 to 5) with a specificity of 100% in the hypothermia group (78.9 
μg/l) compared to the NH group (26.9 μg/l).
Conclusions: Recommended cutoff levels for NSE 72 hours after ROSC do not reliably predict poor neurological 
outcome in cardiac arrest patients treated with MTH. Prospective multicentre trials are required to re-evaluate NSE 
cutoff values for the prediction of neurological outcome in patients treated with MTH.
Introduction
Early prediction of neurological outcome in patients sur-
viving cardiac arrest is a challenging problem. A com-
bined approach using clinical assessment,
electrophysiological studies and biochemical markers has
been proven reliable in predicting poor outcome and is
currently used in most centres [1-3].
Neuron specific enolase (NSE) is a gamma isomer of
enolase that is located in neurons and neuroectodermal
cells. Several studies have evaluated the significance of
NSE to predict neurological outcome in patients after
cardiac arrest. However, the results are not unanimous
regarding outcome prediction and the best cutoff value
for NSE [3-5]. Most authors agree that the NSE serum
level after 72 hours carries the highest predictive value
for neurological outcome after resuscitation [3,5]. In the
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large Prognosis in Postanoxic Coma Study Group
(PROPAC) all patients with NSE levels >33 μg/l at any
time had an unfavourable outcome [6].
With the introduction of mild therapeutic hypothermia
(MTH) the treatment of patients after cardiac arrest has
changed significantly in the last years. Only a minority of
prognostication studies have included patients who
underwent MTH after cardiac arrest. The guidelines pub-
lished in 2006 by the American Academy of Neurology
(AAN) on outcome prediction in comatose survivors
after cardiac arrest recommend a cutoff of 33 μg/l, but
were also mainly based on studies in patients not treated
with hypothermia. Thus, there is an urgent need to re-
evaluate the validity of previously established prognostic
markers in survivors undergoing therapeutic hypo-
thermia [7]. Therefore we conducted an observational
study comparing NSE levels in patients treated with
MTH with historical non-hypothermia (NH) patients.
Materials and methods
The study protocol was approved by the local ethics com-
mittee on human research and is conducted in accor-
dance with the guidelines of the Declaration of Helsinki.
All data were collected within the normal daily intensive
care routine in an anonymous fashion. The institutional
review board therefore waived the need for informed
patient consent. A total number of 230 patients was ana-
lyzed. The hypothermia group (n = 97) was generated
between December 2006 and August 2008 from patients
admitted to our medical intensive care unit (MICU) after
cardiac arrest. All patients received MTH irrespective of
the initial rhythm. A historical NH group in the era prior
to hypothermia treatment was identified in a cohort of
133 patients admitted to our MICU between 2002 and
2004 after cardiac arrest. Detailed characteristics for all
patients included in the study are given in Table 1. Thera-
peutic hypothermia was initiated after admission with an
intravenous infusion of cold saline (4°C, 1,000 to 1,500 ml
bolus) followed by surface cooling with commercially
available non-invasive devices (ArcticSun2000®  Mediv-
ance, Louisville, Colorado, USA). The target temperature
was maintained for 24 hours. Intravenous sedation and
analgesia was induced in all patients by a combination of
midazolam (0.125 mg/kg/h) and fentanyl (0.002 mg/kg/h)
with dose adjustment as needed. Patients undergoing
hypothermia received muscle relaxation with repetitive
administration of pancuronium (0.1 mg/kg) in order to
prevent shivering. Apart from therapeutic hypothermia,
there was no further difference in critical care treatment
between the two groups. In all patient's post-resuscita-
tion treatment was conducted by physicians highly expe-
rienced in critical care according to standard operating
procedures. NSE serum levels were measured 72 hours
after admission to MICU with an enzyme immunoassay
(Elecsys 2010, Roche Diagnostics GmbH, Mannheim,
Germany). The identical test and the same laboratory
were used in both groups compared in this study. Poten-
tial neurological outcome was assessed on the third day
after admission to MICU by clinical examination, NSE
serum levels and somato-sensory evoked potentials,
when needed. In all patients, the decision to continue or
discontinue treatment was taken considering the results
of these tests and with the advice of an external neurolo-
gist.
Clinical outcome was assessed at the time of discharge
from ICU according to the Pittsburgh cerebral perfor-
mance category (CPC) [8]. CPC 1 to 2 were classified as a
favorable neurological outcome whereas CPC 3 to 5 were
regarded as an unfavorable outcome.
The STATA software (Version 10.0; StataCorp; College
Station, Texas, USA) and R (Version 2.8.1; The R Founda-
tion for Statistical Computing, Vienna, Austria) were
used for statistical analysis. According to non parametric
distribution, descriptive parameters are given as median
and inter-quartile range (IQR). Univariate analysis of dif-
ferences between hypothermia patients and the non-
hypothermia group was performed by using the Mann-
Whitney-U test for non-parametric unpaired data and
Fisher's exact test for dichotomous variables. Linear
regression was used to analyze the association of NSE
and several independent variables. Logistic regression
was performed to predict neurological outcome. The
association of NSE and hypothermia treatment was ana-
lyzed by adding an interaction term into the logistic
regression model. Akaike information criterion (AIC)
was used to select the final model. ROC analysis was per-
formed to evaluate the value of NSE for prediction of
neurological outcome. Survival data were analyzed by the
Kaplan-Meier method and comparison between groups
was performed by using the log-rank test.
Results
Baseline parameters
Results of univariate analysis of all patients (n = 230) are
given in Table 1. Concerning APACHE II (Acute Physiol-
ogy and Chronic Health Evaluation II) (P  = 0.003),
bystander cardiopulmonary resuscitation (CPR, P  <
0.001) and epinephrine dosages (P = 0.039), significant
differences were observed between patients in the hypo-
thermia group and the non-hypothermia group. No sig-
nificant differences were found for the other baseline
parameters.
NSE serum levels
NSE serum levels for all patients were significantly lower
under MTH treatment (median, 26.1 μg/l; IQR, 16.4 to
69.8 μg/l) compared to NH (median, 34.1 μg/l; IQR, 21.0
to 150.8 μg/l, P = 0.037, Figure 1a). However, in a linearSteffen et al. Critical Care 2010, 14:R69
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regression model with adjustment for covariates, NSE
was not significantly associated with mild hypothermia
treatment (P = 0.247) whereas time to return of sponta-
neous circulation (ROSC) (P  = 0.008) and ventricular
fibrillation (P = 0.001) showed a significant effect (Table
2).
Neurological outcome (CPC) and NSE ranges
Univariate analysis of neurological outcome (CPC 1 to 2
vs. CPC 3 to 5) showed a significant higher proportion (P
< 0.001) of favorable outcome in patients treated with
hypothermia compared to NH group (hypothermia 54.6%
vs. control 22.5%; Figure 1b). Furthermore, the associa-
tion of neurological outcome, hypothermia treatment
and different ranges of NSE levels was analyzed at Day 3
(Figure 2). In patients with NSE serum levels lower than
20 μg/l the proportion of CPC 1 to 2 was higher in the
hypothermia group (96.6%) versus non-hypothermia
group (76.7%) without reaching significance (P = 0.306).
A significant higher proportion of patients with good
Table 1: Baseline characteristics and neurological outcome of patients treated with mild therapeutic hypothermia (MTH) 
and non-hypothermia (NH) group
NH MTH P-value
(n = 133) (n = 97)
Baseline parameters
Age (years) 64.3 (52.9 to 73.0) 60.3 (51.5 to 70.0) 0.123
Gender
female 33 (24.8) 21 (21.6) 0.638
male 100 (75.2) 76 (78.4)
APACHE II score 26.0 (20.0 to 32.0) 31.0 (24.0 to 34.0) 0.003
Cardiac arrest
Out-of-hospital 101 (75.9) 81 (83.5) 0.190
In-hospital 32 (24) 16 (16.5)
Cardiac rhythm
Shockable rhythm 73 (54.9) 65 (67.0) 0.077
Non-shockable rhythm 60 (45.1) 32 (33.0)
Cause of cardiac arrest
AMI 82 (61.7) 55 (56.7) 0.688
Primary arrhythmia 24 (18) 22 (22.7)
Respiratory 22 (16.5) 18 (18.6)
Other 5 (3.8) 2 (2.1)
Bystander CPR
yes 24 (18.0) 38 (39.2) <0.001
No 109 (82.0) 59 (60.8)
Time to ROSC (minutes) 22 (14 to 30) 20 (12 to 27) 0.176
Total epinephrine dose (mg) 3.0 (2.0 to 5.0) 3.0 (1.0 to 4.5) 0.039
Length of ICU stay (days) 15 (7 to 26) 13 (7 to 23) 0.693
Neurological Outcome
CPC at ICU discharge
1 - good recovery 16 (12) 33 (34) <0.001
2 - moderate disability 14 (10.5) 20 (20.6)
3 - severe disability 5 (3.8) 5 (5.2)
4 - vegetative state 34 (25.6) 5 (5.2)
5 - death 64 (48.1) 34 (35.1)
Data are presented as median (25th to 75th percentiles) or as absolute numbers (%). CPR, cardiopulmonary resuscitation, ROSC, return of 
spontaneous circulation, CPC, cerebral performance category, NSE, neuron specific enolase, AMI, acute myocardial infarction, APACHE, Acute 
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neurological outcome (CPC 1 to 2) was observed for NSE
levels in the range of 20 to 40 μg/l (P < 0.001) as well as in
the group of patients with NSE levels in the range of 40 to
80 μg/l (P = 0.030). Patients with an NSE greater than 80
μg/l showed a bad neurological outcome in both groups
(CPC 3 to 5; MTH n = 21, NH n = 45, Figure 2).
Interaction of CPC, NSE and hypothermia
The association of neurological outcome (CPC 1 to 2 vs. 3
to 5), NSE serum levels and MTH was adjusted for con-
founders using a logistic regression model including gen-
der, age, APACHE II-score, epinephrine dosage,
bystander CPR, time to ROSC, location of cardiac arrest
and initial heart rhythm as independent variables. The
model for neurological outcome (CPC 1 to 2 vs. 3 to 5)
identified NSE (P < 0.001), the interaction of NSE serum
level and mild hypothermia treatment (P = 0.002) as well
as time to ROSC (P = 0.017) as predictors of neurological
outcome (Table 3). The interaction between NSE serum
levels, applied treatment and neurological outcome is
demonstrated in Figure 3 showing the predicted proba-
bilities for CPC 3 to 5 in relation to NSE serum levels and
Table 2: Linear regression model of NSE serum levels
Coefficient 95%-CI P-value
lower upper
(Intercept) 182.76 73.18 292.34 0.001
Gender female -5.79 -42.37 30.79 0.755
Age (year) -1.16 -2.25 -0.07 0.037
APACHE II score 0.98 -1.07 3.04 0.348
Hypothermia 
treatment
-16.29 -48.86 16.28 0.325
Bystander CPR -36.89 -72.43 -1.35 0.042
T i m e  t o  R O S C  ( m i n ) 1 . 8 50 . 6 63 . 0 3 0 . 0 0 2
Ventricular fibrillation -49.14 -80.76 -17.51 0.002
R-squared: 0.136
CPR, cardiopulmonary resuscitation; ROSC, return of spontaneous circulation; CI, confidence interval; min, minutes
Figure 1 NSE serum levels (a) and neurological outcome (b) of patients treated with mild hypothermia and non-hypothermia group.
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hypothermia treatment. In the range of NSE serum levels
between approximately 25 and 100 μg/l hypothermia
treatment is associated with a lower probability of unfa-
vorable neurological outcome (CPC 3 to 5) compared to
the NH group whereas in the range of NSE levels >100
μg/l the probabilities for CPC 3 to 5 of hypothermia and
non-hypothermia group show close approximation.
ROC analysis of outcome
ROC analysis for the prediction of a poor neurological
outcome (CPC 3 to 5, Figure 4) showed a higher area
under curve (AUC) in the non-hypothermia group (AUC
0.94) compared to the hypothermia group (AUC 0.88).
The best NSE cutoff value (shortest distance to left upper
corner) was higher under hypothermia treatment (31.8
μg/l; sensitivity 79.5%; specificity 88.7%) compared to the
non-hypothermia group (22.4 μg/l; sensitivity 86.4%;
specificity 90%). Cutoff values predicting unfavorable
outcome (CPC 3 to 5) with a specificity of 100% were also
higher in the hypothermia group (78.9 μg/l) compared to
non-hypothermia (26.9 μg/l).
Figure 2 Association of neurological outcome (CPC 1-2 vs. CPC 3-5) and NSE serum level ranges.
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Survival analysis
Kaplan-Meier analysis revealed a probability for 365-day
survival of 45.9% (CI 33.3 to 57.7%) in the hypothermia
group compared to 27.4% (CI 19.8 to 35.5%) in the non-
hypothermia group. The log rank test was significant (P =
0.006; Figure 5).
Discussion
Determination of serum NSE is an established tool for
outcome prediction after cardiac arrest [5,9,10]. Never-
theless, post-resuscitation care has changed considerably
with the introduction of therapeutic hypothermia in
recent years. In general, outcome prediction may be more
difficult in patients treated with hypothermia [11,12]. In
particular, the role of NSE levels for outcome prediction
in patients treated with MTH has only been investigated
in a few studies with conflicting results [13,14]. There-
fore, the predictive value of NSE in patients receiving
MTH treatment requires re-evaluation.
The univariate analysis in the present study revealed a
significantly lower median NSE serum level (72 hours
Table 3: Logistic regression of neurological outcome (CPC 1 to 2 versus CPC 3 to 5)
OR 95%-CI P-value
lower Upper
N S E 1 . 3 11 . 1 51 . 5 0 < 0 . 0 0 1
Hypothermia 17.44 1.03 296.62 0.048
N S E * h y p o t h e r m i a 0 . 8 10 . 7 10 . 9 2 0 . 0 0 1
Gender female 2.43 0.86 6.88 0.096
Age (year) 1.03 0.99 1.06 0.158
A P A C H E  I I  s c o r e 0 . 9 90 . 9 31 . 0 5 0 . 6 1 8
T i m e  t o  R O S C  ( m i n ) 1 . 0 30 . 9 91 . 0 7 0 . 1 7 2
B y s t a n d e r  C P R 0 . 9 30 . 3 72 . 3 3 0 . 8 7 8
Ventricular fibrillation 0.55 0.21 1.44 0.223
Pseudo R-squared: 0.557
CPR, cardiopulmonary resuscitation; ROSC, return of spontaneous circulation; CI, confidence interval; min, minutes.
Figure 3 Interaction of NSE serum level and mild hypothermia 
treatment (MTH) for prediction of neurological outcome.
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after admission to hospital) under mild hypothermia
compared to the non-hypothermia group. This result is in
line with the published hypothesis of Tiainen et al. that
the neuroprotective effect of hypothermia would be
accompanied by diminished release of NSE [14]. Tiainen
et al. analyzed the effect of therapeutic hypothermia on
levels of serum NSE performing serial measurements at
24, 36 and 48 hours after cardiac arrest. In a repeated
measurement analysis the levels of NSE were significant
lower in patients treated with hypothermia compared to
control group. However, the median of NSE at 48 hours
(7.9 μg/l; IQR, 5.9 to 13.9 μg/l) in the hypothermia group
was only slightly lower compared to the control group
(median 8.6 μg/l; IQR, 5.2 to 20.2 μg/l). After adjusting
our data for confounders, hypothermia treatment showed
only a trend to lower NSE values without reaching signif-
icance. However, the low r-square of this model indicates
that further unknown important factors may be relevant.
To analyze the association of NSE, neurological out-
come and MTH treatment after cardiac arrest, we used a
logistic regression model revealing that the neurological
outcome was associated with hypothermia treatment and
the interaction term of NSE and hypothermia treatment.
This interaction demonstrates that the relation between
NSE and neurological outcome is modified by hypo-
thermia treatment (Figure 3). Thus, the effect of hypo-
thermia on neurological outcome differs substantially in
comparison to the non-hypothermia group, depending
on serum NSE level at 72 hours. The greatest therapeutic
effect of hypothermia was observed in patients with NSE
levels between 20 and 80 μg/l whereas in patients with
high (>80 μg/l) or low (<20 μg/l) NSE levels the difference
to patients not treated with hypothermia proved to be
limited. Therefore, MTH may not only result in lower
NSE levels but it appears to be associated with the proba-
bility of a better neurological outcome in patients treated
with MTH in comparison to NH patients with similar
NSE levels.
The results of the ROC analysis are a further indicator
that the relation between NSE and neurological outcome
is substantially modified by hypothermia treatment as the
non-hypothermia group revealed a higher area under
curve (AUC, 0.94) compared to the hypothermia group
(AUC, 0.88). This trend towards a reduced discrimina-
tory power of serum NSE levels for poor neurological
outcome under hypothermia treatment was also found by
Tiainen et al. with an AUC of 0.89 in the control group
compared to an AUC of 0.80 [14].
In our series, cutoff values predicting unfavorable out-
come (CPC 3 to 5) with a specificity of 100% were higher
in the MTH group (78.9 μg/l) compared to NH group
(26.9 μg/l) resulting in a cutoff-ratio (MTH/NH) of 78.9/
26.9 = 2.9. Tiainen et al. published a cutoff of 25.0 μg/l for
NSE at 48 hours predicting six-month neurological out-
come with a 100% specificity after MTH and 8.8 μg/l for
the NH group (cutoff-ratio, 25.0/8.8 = 2.84) [14].
Although the level of NSE cutoff is lower compared to
our study, the NSE-cutoff-ratios are similar. Oksanen et
al. found a cutoff of 33 μg/l of NSE at 48 hours predicting
poor six-month neurological outcome with a specificity
of 100% whereas Rundgren et al. obtained a NSE cutoff of
27.7 μg/l at 48 hours and 27.3 μg/l at 72 hours [15,16].
The comparability of absolute NSE values for predic-
tion of neurological outcome seems to be limited as cut-
offs are presumably affected by multiple parameters
including time to NSE measurement, laboratory immu-
noassay, cause of cardiac arrest, in-/out-of-hospital car-
diac arrest, time to ROSC and outcome definition.
Especially different methods of NSE analysis may inter-
fere with a comparison of results from different laborato-
ries. The present study assessed NSE values at 72 hours
after admission to hospital. This time point was shown to
be superior for prediction of neurological outcome in
non-hypothermia cardiac arrest patients [5,9,10]. How-
ever, the ideal time point for measurement of NSE in
patients treated with MTH for predicting outcome is still
unclear. In a recent study, ROC analysis of neurological
outcome showed an almost similar AUC (0.84) for NSE at
72 hours compared to NSE at 48 hours (AUC 0.83),
whereas the threshold with 100% specificity of NSE at 48
hours was associated with a higher sensitivity (67%) com-
pared to NSE at 72 hours (50%) [16]. Current published
data suggest that the time course of NSE serum levels
might be a better predictor for outcome than a single
measurement of NSE.
Figure 5 Kaplan-Meier survival curves of hypothermia and non-
hypothermia group.
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This study also has some limitations that should be
pointed out. Results were obtained from a single-centre
trial using a retrospective sample of non-hypothermia
patients rather than from a prospective randomized
study. However, due to the fact that the current guidelines
clearly recommend mild hypothermia treatment after
cardiac arrest, a prospective randomized trial comparing
hypothermia and non-hypothermia is ethically not
acceptable. With our retrospective study design it cannot
be excluded that along with the implementation of hypo-
thermia treatment post-resuscitation care has developed
and improved in general. Moreover, we did not collect
data on neurological long-term outcome. However, it has
been shown that CPC scores at hospital discharge may
undergo only minor changes in the following six months
[17-19].
A general problem in all studies on prognostication is
the fact that these trials are susceptible to self-fulfilling
prophecies. In our analysis, NSE levels were not blinded
to the physicians in charge. Nevertheless, the process of
decision making on therapy withdrawal in patients with
poor neurological prognosis always consisted of a combi-
nation of clinical, electrophysiological and biochemical
tests, which is in line with current practice [1,2,20]. As
s t a t e d  i n  t h e  m e t h o d  s e c t i o n ,  b o t h  g r o u p s  o f  p a t i e n t s
received full ICU support over the first three days. Fur-
thermore the length of ICU stay was shorter in the hypo-
thermia group compared to the control group.
From the pathophysiological point of view our data are
somewhat surprising. According to our results, patients
treated with hypothermia stand a good chance of recov-
ery despite higher levels of NSE. However, it cannot be
fully ruled out that higher NSE levels in the hypothermia
group may partly be due to factors other than hypoxic
brain damage, for example a higher proportion of
patients with non-convulsive status epilepticus. A current
study by DeGiorgio et al. evaluated the NSE release in dif-
ferent subtypes of status epilepticus. The mean peak NSE
level for non-convulsive status epilepticus was 37.83 ng/
ml [21]. Moreover, the incidence of non-convulsive status
epilepticus in survivors after cardiac arrest undergoing
hypothermia amounts to 10% and appears to herald a
fatal disease course in most patients [22]. Although we
did not routinely perform electroencephalography in all
patients, these data show that a higher incidence of status
epilepticus does not sufficiently explain the differences in
NSE levels between the groups.
Another possibility is that NSE serum levels reflect dif-
ferent mechanisms of neuronal damage that are differen-
tially affected by MTH. Support for this hypothesis
comes from investigation of stroke patients. Wunderlich
et al. measured NSE on admission and on each of the first
four days after stroke [23]. An early first NSE peak was
interpreted as due to a rapid release out of the initially
damaged tissue, followed by a second peak at 72 hours
reflecting secondary mechanisms of brain damage, ongo-
ing neuronal cell death or persistent disturbance of the
blood brain barrier. NSE release in patients after resusci-
tation was found to peak after 72 hours in the majority of
published studies including patients without hypo-
thermia treatment. It remains to be demonstrated
whether mild hypothermia treatment affects NSE release
especially in the late phase after 48 to 72 hours where
reperfusion injury, ongoing cell death, edema and dys-
function of the blood brain barrier take place. Therefore a
different NSE kinetic in patients undergoing hypothermia
is possible and the best time point for neurological out-
come prediction with NSE is obviously still unknown in
patients treated with MTH.
Conclusions
In summary, in patients after cardiac arrest, single mea-
surements of NSE should be interpreted with caution as
many patient- and treatment-related factors may influ-
ence the amount and kinetics of NSE release. In accor-
dance with our results, NSE levels drawn 72 hours after
ROSC correlated poorly with neurological outcome
according to current recommended cutoffs in patients
treated with MTH. Therefore the usefulness of current
NSE cutoff values for prognosis during post-resuscitation
care seems limited in these patients. Decision on treat-
ment continuation or discontinuation should therefore
always be based on a full assessment of complimentary
clinical observations and neurophysiological testing.
Key messages
• The calculated interaction between NSE and hypo-
thermia treatment was a significant outcome predic-
tor.
• Survivors undergoing hypothermia treatment had
remarkably higher NSE cutoff levels for bad outcome
(CPC 3 to 5) compared to non-hypothermia patients.
• Currently recommended NSE cutoff levels after
resuscitation do not reliably predict poor outcome.
• The probability for 365-day survival was signifi-
cantly higher after hypothermia treatment.
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